Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00114777
Registration number
NCT00114777
Ethics application status
Date submitted
17/06/2005
Date registered
20/06/2005
Date last updated
7/07/2017
Titles & IDs
Public title
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Query!
Scientific title
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Query!
Secondary ID [1]
0
0
IM103-027
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BENEFIT-EXT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Renal Transplantation
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cyclosporin A
Treatment: Drugs - Belatacept Less Intensive Regimen (LI)
Treatment: Drugs - Belatacept More Intensive Regimen (MI)
Active comparator: Cyclosporin A -
Experimental: Belatacept Less Intensive Regimen (LI) -
Experimental: Belatacept More Intensive Regimen (MI) -
Treatment: Drugs: Cyclosporin A
tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
Treatment: Drugs: Belatacept Less Intensive Regimen (LI)
solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
Treatment: Drugs: Belatacept More Intensive Regimen (MI)
solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Survived With a Graft at 12 Months Post-Transplant
Query!
Assessment method [1]
0
0
Participant and graft survival at 12 months was summarized within each treatment group. Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine = 6.0 mg/dL (530 µmol/L) as determined by central laboratory for =4 weeks or 56 or more consecutive days of dialysis.
Query!
Timepoint [1]
0
0
Month 12 post-transplant
Query!
Primary outcome [2]
0
0
Percentage of Participants With a Measured Glomerular Filtration Rate (GFR) <60 mL/Min Per 1.73 m^2 at Month 12 or a Decrease in Measured GFR >=10 mL/Min Per 1.73 m^2 From Month 3 to Month 12
Query!
Assessment method [2]
0
0
GFR was assessed using a true measure of glomerular filtration via non-radiolabeled iothalamate clearance test using a validated procedure.
Query!
Timepoint [2]
0
0
From Month 3 to Month 12
Query!
Secondary outcome [1]
0
0
Measured Glomerular Filtration Rate (GFR) by Month 12 and 24
Query!
Assessment method [1]
0
0
GFR was assessed using a true measure of glomerular filtration via nonradiolabeled iothalamate clearance test using a validated procedure. Missing measured GFR assessments were imputed. Here, 'n' signifies the number of evaluable participants for the reporting arm at the given time point. Missing measured GFR assessments were imputed to a GFR of zero.
Query!
Timepoint [1]
0
0
At Month 12 and Month 24
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Chronic Allograft Nephropathy (CAN) at Month 12
Query!
Assessment method [2]
0
0
Biopsy-proven CAN was determined by a blinded central histopathologist using the Banff 97 working classification of kidney transplant pathology. Onset of CAN was determined by the biopsy date when it was observed. Participants were considered as having CAN at 12 months if: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; Participant had graft loss during the first year post transplant; no biopsy available post 12 months and CAN not observed in biopsies prior to 12 months; no biopsy available either prior to or post 12 months; and the measured glomerular filtration rate from Month 3 to Month 12 decreases at least 10 mL/min/1.73m\^2. All other participants with missing 12 month biopsy were considered having no CAN observed at 12 months.
Query!
Timepoint [2]
0
0
At Month 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants Who Survived With a Graft at 24 and 36 Months Post-Transplant
Query!
Assessment method [3]
0
0
Participant and graft survival at 12 months was summarized within each treatment group. Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss will be defined as a sustained level of serum creatinine = 6.0 mg/dL (530 µmol/L) as determined by central laboratory for = 4 weeks or 56 or more consecutive days of dialysis.
Query!
Timepoint [3]
0
0
Month 24 and Month 36 post-transplant
Query!
Secondary outcome [4]
0
0
Calculated Glomerular Filtration Rate (GFR) at 6, 12, 24, 36 and 84 Months
Query!
Assessment method [4]
0
0
GFR was assessed using a true measure of glomerular filtration via nonradiolabeled iothalamate clearance test using a validated procedure. Missing measured GFR assessments were imputed. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [4]
0
0
Months 6, 12, 24, 36 and 84
Query!
Secondary outcome [5]
0
0
Change in Calculated GFR at Months 12, 24, 36 and 84
Query!
Assessment method [5]
0
0
GFR was assessed using a true measure of glomerular filtration via nonradiolabeled iothalamate clearance test using a validated procedure. Missing measured GFR assessments were imputed. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [5]
0
0
Baseline and Months 12, 24, 36 and 84
Query!
Secondary outcome [6]
0
0
Number of Participants With Anti-Hypertensive Medications Used to Control Hypertension at 12, 24 and 36 Months
Query!
Assessment method [6]
0
0
Participants were determined to have hypertension at a particular time point if standardized systolic blood pressure = 130 mm Hg or standardized diastolic blood pressure = 80 mm Hg or participant had received an antihypertensive medication(s) for hypertension. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [6]
0
0
Baseline and Months 12, 24 and 36
Query!
Secondary outcome [7]
0
0
Percentage of Subjects Who Used Anti-Hypertensive Medications to Control Hypertension at Months 12, 24 and 36
Query!
Assessment method [7]
0
0
Participants were determined to have hypertension at a particular time point if standardized systolic blood pressure = 130 mm Hg or standardized diastolic blood pressure = 80 mm Hg or subject had received an anti-hypertensive medication(s) for hypertension. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [7]
0
0
Months 12, 24 and 36
Query!
Secondary outcome [8]
0
0
Percentage of Participants With New Onset Diabetes Mellitus (NODM) at 12, 24 and 36 Months.
Query!
Assessment method [8]
0
0
NODM was defined as participant who did not have diabetes prior to randomization. Participants were determined for NODM if the participant received an antidiabetic medication for a duration of at least 30 days, or at least two fasting plasma glucose (FPG) tests indicate that FPG is = 126 mg/dL (7.0 mmol/L).
Query!
Timepoint [8]
0
0
Months 12, 24 and 36
Query!
Secondary outcome [9]
0
0
Systolic and Diastolic Blood Pressure (BP) at 12, 24 and 36 Months
Query!
Assessment method [9]
0
0
Participants were determined to have hypertension at a particular time point if standardized systolic blood pressure = 130 mm Hg or standardized diastolic blood pressure = 80 mm Hg or participant had received an anti-hypertensive medication(s) for hypertension. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [9]
0
0
Months 12, 24 and 36
Query!
Secondary outcome [10]
0
0
Mean Framingham Risk Score From Baseline to Months 12, 24 and 36
Query!
Assessment method [10]
0
0
The risk score was calculated based on the total points from six variables: Age, Level of LDL-cholesterol, Level of HDL-cholesterol, Presence and severity of systolic or diastolic hypertension, Presence or absence of a history of diabetes mellitus and Presence or absence of a history recent cigarette smoking. Total scores can range from \<-3 to \>14, which translate to a 1% to 56% risk of developing coronary heart disease in 10 years. Totals in the 4 to 6 point range translate to a 7 to 11% risk and 8 to 10 point range translate to a 18 to 27% risk.
Query!
Timepoint [10]
0
0
Baseline and Months 12, 24 and 36
Query!
Secondary outcome [11]
0
0
Percentage of Participants Using Lipid-Lowering Therapy at 12, 24, and 36 Months
Query!
Assessment method [11]
0
0
Dyslipidemia was defined as triglyceride = 500 mg/dL \[5.65 mmol/L\], low density lipoprotein (LDL) = 100 mg/dL \[2.59 mmol/L\], and non-elevated high density lipoprotein (HDL) = 130 mg/dL \[3.36 mmol/L\]. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [11]
0
0
Months 12, 24 and 36
Query!
Secondary outcome [12]
0
0
Change in Total Cholesterol (TC), Non-HDL, LDL and HDL Cholesterol and Triglycerides at 12, 24 and 36
Query!
Assessment method [12]
0
0
Dyslipidemia was defined as triglyceride = 500 mg/dL \[5.65 mmol/L\], low density lipoprotein (LDL) = 100 mg/dL \[2.59 mmol/L\], and elevated non-high density lipoprotein (HDL) = 130 mg/dL \[3.36 mmol/L\]. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [12]
0
0
Months 12, 24 and 36
Query!
Secondary outcome [13]
0
0
Percentage of Participants Who Have an Acute Rejection by Months 6, 12, 24, 36 and 84
Query!
Assessment method [13]
0
0
Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Clinically suspected acute rejection was defined as an unexplained rise of serum creatinine = 25% from baseline creatinine or an unexplained decreased urine output or fever and graft tenderness or serum creatinine that remains elevated within 14 days post--transplantation and clinical suspicion of acute rejection exists.
Query!
Timepoint [13]
0
0
Months 6, 12, 24, 36 and 84
Query!
Secondary outcome [14]
0
0
Number of Participants Using Lymphocyte Depleting Therapy and Steroid-Resistant for Acute Rejection by Months 6, 12, 24, and 36.
Query!
Assessment method [14]
0
0
Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Lymphocyte -depletion therapy for treatment of an episode of acute was defined as a participant treated with therapy and provided not treated with steroids earlier while steroid resistant acute rejection was defined as participants initially treated with steroids alone for suspected acute rejection for at least 2 days and then followed by the start of lymphocyte -depletion therapy.
Query!
Timepoint [14]
0
0
Months 6, 12, 24 and 36
Query!
Secondary outcome [15]
0
0
Number of Participants Based on Severity of Acute Rejection Based on Banff Grade Level by Months 6, 12, 24, 36 and 84
Query!
Assessment method [15]
0
0
Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Clinically suspected acute rejection was defined as an unexplained rise of serum creatinine = 25% from baseline creatinine or an unexplained decreased urine output or fever and graft tenderness or serum creatinine that remains elevated within 14 days post--transplantation and clinical suspicion of acute rejection exists.
Query!
Timepoint [15]
0
0
Months 6, 12, 24, 36 and 84
Query!
Secondary outcome [16]
0
0
Mean Changes in Mental Component and Physical Component Health-Related Quality of Life (SF-36) From Baseline to Months 12, 24 and 36
Query!
Assessment method [16]
0
0
The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life (QOL) and comprises 8 domains, including 4 physical (physical health, bodily pain, physical functioning and physical role limitations) and 4 mental (mental health, vitality, social functioning, and emotional role limitation) subscales. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QOL (0=Poorest Health; 100=Best Health). Mean change from baseline = post-baseline value - baseline value; a higher value signifies improvement.
Query!
Timepoint [16]
0
0
Baseline and Months 12, 24 and 36
Query!
Secondary outcome [17]
0
0
Number of Participants With Clinically Significant Changes in Vital Signs up to 36 Months
Query!
Assessment method [17]
0
0
Participants with abnormal blood pressure, body weight and body temperature outside the defined normal range were graded as clinically significant vital signs by the investigator.
Query!
Timepoint [17]
0
0
Day 1 to Month 36
Query!
Secondary outcome [18]
0
0
Number of Participants With Laboratory Test Abnormalities up to 36 Months
Query!
Assessment method [18]
0
0
Participants with laboratory values outside the defined normal range were graded as clinically significant laboratory abnormalities by the investigator. Subjects were analyzed for Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase(AST), Hemoglobin, Platelet Count, Leukocytes, Bilirubin, Creatinine, Calcium, Bicarbonate, Potassium, Magnesium, Sodium, Phosphorus, Albumin, Uric Acid and Protein. Laboratory abnormalities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively.
Query!
Timepoint [18]
0
0
Day 1 to Month 36
Query!
Secondary outcome [19]
0
0
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 36
Query!
Assessment method [19]
0
0
AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
Query!
Timepoint [19]
0
0
Day 1 to Month 36
Query!
Secondary outcome [20]
0
0
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 84
Query!
Assessment method [20]
0
0
AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
Query!
Timepoint [20]
0
0
Day 1 to Month 84
Query!
Secondary outcome [21]
0
0
Percentage of Participants With Graft Loss or Death to Month 84
Query!
Assessment method [21]
0
0
Participant and graft survival at 84 months was summarized within each treatment group.
Query!
Timepoint [21]
0
0
Randomization to date of death, up to 84 months
Query!
Eligibility
Key inclusion criteria
* Subject is a first-time recipient of a kidney transplant from a deceased donor.
* Specific donor criteria
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Donor age <10 years
* Subjects receiving a concurrent solid organ or cell transplant (lung, heart, etc.)
* Subjects with a positive T-cell lymphocytotoxic crossmatch.
* Subjects who are positive for Hepatitis B or C, or HIV
* Active tuberculosis
* History of cancer in the last 5 years
* History of substance abuse
* Specific laboratory results are exclusionary
* Mammography suspicious for cancer
* Allergy to iodine
* For Long-term extension study-Subjects who have completed three years of study treatment (through Week 156)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
595
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
Local Institution - Woodville
Query!
Recruitment postcode(s) [1]
0
0
5011 - Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Wisconsin
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Buenos Aires
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Cordoba
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Santa Fe
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Innsbuck
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Vienna
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Leuven
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Rio Grande Do Sul
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Sao Paulo
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Rio De Janeiro
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Alberta
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Nova Scotia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Quebec
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Saskatchewan
Query!
Country [31]
0
0
Chile
Query!
State/province [31]
0
0
Metropolitana
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Prague 4
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Bordeaux
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Brest, Cedex 29
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Creteil
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Le Kremlin Bicetre Cedex
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Nante Cedex 01
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Paris
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Toulouse Cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Tours Cedex 09
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Vandoeuvre Les Nancy Cedex
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Berlin
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Erlangen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Essen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Hannover
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Budapest
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Szeged
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Milano
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Padova
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Roma
Query!
Country [51]
0
0
Norway
Query!
State/province [51]
0
0
Oslo
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Poznan
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Warszawa
Query!
Country [54]
0
0
South Africa
Query!
State/province [54]
0
0
Gauteng
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Barcelona
Query!
Country [56]
0
0
Spain
Query!
State/province [56]
0
0
Madrid
Query!
Country [57]
0
0
Spain
Query!
State/province [57]
0
0
Malaga
Query!
Country [58]
0
0
Sweden
Query!
State/province [58]
0
0
Gothenburg
Query!
Country [59]
0
0
United Kingdom
Query!
State/province [59]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00114777
Query!
Trial related presentations / publications
Dobbels F, Wong S, Min Y, Sam J, Kalsekar A. Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials. Transplantation. 2014 Nov 15;98(9):960-8. doi: 10.1097/TP.0000000000000159. Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, Garcia VD, Kamar N, Lang P, Manfro RC, Massari P, Rial MD, Schnitzler MA, Vitko S, Duan T, Block A, Harler MB, Durrbach A. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012 Mar;12(3):630-9. doi: 10.1111/j.1600-6143.2011.03914.x. Epub 2012 Feb 2.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00114777
Download to PDF